This site is intended for US-based population health managers only.

Resource Hub for Population 
Health Management

Managing populations with chronic kidney disease (CKD) with type 2 diabetes (T2D) and/or heart failure often requires a multidisciplinary treatment approach due to the complex nature of these conditions, high comorbidity burden, and high rates of hospitalizations.1-4

heart and CKD

Managing populations with chronic kidney disease (CKD) with type 2 diabetes (T2D) and/or heart failure often requires a multidisciplinary treatment approach due to the complex nature of these conditions, high comorbidity burden, and high rates of hospitalizations.1-4

As part of Bayer’s commitment to improving the quality of care and population health outcomes, this Resource Hub for Population Health Management was designed to provide resources to help you optimize treatment strategies and patient outcomes.

Select your therapeutic area and audience type to access tailored downloadable content and resources.

Heart Failure

~7.72 million patients have heart failure in the United States5

Alt tag
Alt tag

CKD with T2D

~40% of the 36.4 million Americans with T2D will develop CKD9,10

Alt tag
Alt tag

ACCORD, Action to Control Cardiovascular Risk in Diabetes; CKD, chronic kidney disease;
ICD-10, International Classification of Diseases, Tenth Revision; NHANES, National Health and Nutrition Examination Survey; T2D, type 2 diabetes.

*Retrospective study of 60,514 adults ≥18 years in the Nationwide Readmission Database who were hospitalized for acute or acute on chronic HFpEF according to an ICD-10 diagnosis code of I5031 or acute on chronic HFpEF.8

Longitudinal study of 39,982 patients ≥65 years in the Get With The Guidelines®-Heart Failure registry, linked with U.S. Centers for Medicare & Medicaid Services claims data from Jan 1, 2005 through Dec 30, 2009.2

Multicenter randomized controlled study of 12,537 high-risk patients with prediabetes or early T2D.11

§Retrospective analysis of the ACCORD trial, a randomized study of 10,251 patients with T2D.12

Cross-sectional analysis of adults with T2D from 3 US NHANES datasets developed during 2007-2012.13

References: 1. Bozkurt B, et al. J Card Fail. 2025;31(1):66-116. 2. Shah KS, et al. J Am Coll Cardiol. 2017;70(20):2476-2486. 3. Wu B, et al. BMJ Open Diabetes Res Care. 2016;4(1):e000154. 4. Schrauben SJ, et al. PLoS Med. 2020;17(12):e1003470. 5. Racine M, et al. CardioVascular Resource Group. CVrg Market Strategies Heart Failure 4Q 2024. 6. Olchanski N, et al. Cardiovasc Endocrinol Metab. 2020;9(1):17-23. 7. Racine M, et al. CardioVascular Resource Group. CVrg Market Strategies Heart Failure 3Q 2024. 8. Jha AK, et al. World J Cardiol. 2022;14(9):473-482. 9. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed April 15, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html#:~:text=Prevalence%20of%20both%20diagnosed%20and,the%20U.S.%20population—had%20diabetes 10. Bailey RA, et al. BMC Res Notes. 2014;7:415. 11. Papademetriou V, et al. Am J Med. 2017;130(12):1465.e27-1465.e39. 12. Papademetriou V, et al. Kidney Int. 2015;87(3):649-659. 13. Wu B, et al. BMJ Open Diabetes Res Care. 2016;4(1):e000154. 14. American Diabetes Association Professional Practice Committee. Diabetes Care. 2025;48(suppl 1):S239-S251. 15. Alfego D, et al. Diabetes Care. 2021;44(9):2025-2032.